Efficacy and safety of olverembatinib as maintenance therapy after allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia

血液学 医学 淋巴细胞白血病 肿瘤科 移植 造血干细胞移植 造血细胞 内科学 维持疗法 造血 急性白血病 费城染色体 白血病 干细胞 急性淋巴细胞白血病 免疫学 化疗 生物 染色体易位 遗传学 基因
作者
Jun Kong,Fengmei Zheng,Chen‐Hua Yan,Jingzhi Wang,Haixia Fu,Zhidong Wang,Pan Suo,Guan-Hua Hu,Meng Lv,Huan Chen,Xiao‐Dong Mo,Lan‐Ping Xu,Xiaohui Zhang,Xiaojun Huang,Yu Wang
出处
期刊:Annals of Hematology [Springer Science+Business Media]
标识
DOI:10.1007/s00277-025-06198-0
摘要

Abstract Experience using olverembatinib as maintenance therapy in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) after allogeneic hematopoietic cell transplantation (allo-HCT) is limited. We retrospectively collected data from 26 patients with Ph + ALL who received only olverembatinib as maintenance therapy after allo-HCT. Olverembatinib was administered as prophylaxis in 18 patients (69.2%), and preemptively in 8 patients (30.8%). The median time of olverembatinib initiation after transplantation was 2.5 months (range, 1-7.3). The median starting dose of olverembatinib was 35 mg qod (range, 15–40). The median duration of olverembatinib treatment was 12.5 months (range, 6–23). Olverembatinib maintenance treatment was discontinued in 8 patients (8/26,30%), seven stopped the drug for a long-lasting BCR-ABL1 negativity and 1 for recurrent fever associated with the drug. BCR-ABL1 turned positive in 3 patients in 2, 3 and 6 months after discontinuation. During olverembatinib treatment, three patients developed grade ≥ 3 hematologic side effects, which resolved with dose interruption or dose reduction. The median follow-up time after allo-HCT were 17.75 months (range 7–31). The hematologic relapse rate was 7.7% (2/26), with no event in the preemptive group. The 3-year probability of overall survival and relapse free survival after allo-HCT was 91.7% and 79.1%, respectively. Only one patient in prophylaxis group died of central central nervous system (CNS) relapse. Thus, our data suggest that olverembatinib is effective and safe as maintenance treatment in patients with Ph + ALL who underwent allo-HSCT. The main adverse effect was hematologic toxicity, which was tolerated.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wqx完成签到,获得积分10
刚刚
troyqiujing完成签到,获得积分0
1秒前
1秒前
一二三完成签到,获得积分10
1秒前
忧虑的凌雪完成签到,获得积分10
1秒前
传奇3的应助被ericaxixi采纳,获得10
1秒前
hsing完成签到,获得积分10
1秒前
虚室生白完成签到,获得积分10
1秒前
鲸落发布了新的文献求助10
2秒前
syl发布了新的文献求助10
2秒前
勤劳冰安完成签到,获得积分10
2秒前
HowesFeng完成签到,获得积分10
3秒前
123444发布了新的文献求助10
3秒前
yyy完成签到,获得积分10
3秒前
TAOS完成签到,获得积分10
3秒前
3秒前
Suzi完成签到 ,获得积分10
3秒前
姜磊宇完成签到,获得积分10
4秒前
Aki_27完成签到,获得积分10
4秒前
jiachun完成签到,获得积分10
4秒前
小二郎的应助被研友_841dlL采纳,获得10
5秒前
万能图书馆的应助被挽梦丸子采纳,获得10
5秒前
lww完成签到,获得积分10
6秒前
6秒前
6秒前
David123完成签到,获得积分10
6秒前
害羞菲鹰完成签到,获得积分10
6秒前
hyr完成签到 ,获得积分10
7秒前
浮生若梦完成签到,获得积分10
7秒前
Nicole完成签到,获得积分10
7秒前
LLL发布了新的文献求助10
7秒前
AAA完成签到,获得积分10
8秒前
ket的应助被小巧凡梅采纳,获得10
8秒前
123444完成签到,获得积分10
8秒前
OrangeMoon完成签到,获得积分10
8秒前
9秒前
倒拔垂杨柳的应助被tanshy采纳,获得10
9秒前
龙骑完成签到 ,获得积分10
9秒前
Kamal完成签到,获得积分10
9秒前
木木木完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173580
求助须知:如何正确求助?哪些是违规求助? 9565737
关于积分的说明 21782083
捐赠科研通 7767775
什么是DOI,文献DOI怎么找? 3431604
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476870